|
Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor Clinical research trials and Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor. Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor clinical trial. Subjects frequently get the best healthcare possible for their Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor  Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor
Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor
For Condition: HIV Infection
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: This study will continue to follow children who participated in an earlier National Cancer Institute trial of HIV treatment with a protease inhibitor. Children in this study will receive a combination of at least three drugs that include at least one protease inhibitor and one reverse transcriptase inhibitor. The study will examine to what extent these drugs can restore immune function in HIV-infected children and over what length of time. It will look at changes in the amounts of virus and the specific types of immune cells in the body over the 96-week trial period. It will also examine patients' immune system response to influenza and tetanus vaccinations. The children will either continue to receive the anti-HIV drugs they have been taking, or their medicines will be changed to a different combination of protease inhibitor and reverse transcriptase inhibitor. Before and during the study, patients will undergo various tests, including a physical examination, blood tests and chest X ray, immune response tests, CT scan, eye examination, electrocardiogram and echocardiogram. A procedure called apheresis may be done to collect white blood cells. In this procedure, whole blood is drawn similar to donating blood, the white cells are separated out by a machine, and the red cells are returned to the body.
Details: This study will evaluate the extent of immunoreconstitution in children receiving combination antiretroviral therapy that includes a protease inhibitor and reverse transcriptase inhibitors. The children who will be evaluated and followed in this study are those who have previously been studied on other protease inhibitor-containing anti-HIV protocols within the HIV and AIDS Malignancy Branch. This study will provide a mechanism to assess the long-term immunologic changes of potent combination therapy in this unique population and to relate this to the virologic changes. A total of 50 HIV-1 infected children will be studied. The children enrolled in this protocol will either continue their current combination of protease inhibitor and reverse transcriptase therapy or, if deemed clinically appropriate, will be changed to a new, best available combination of protease inhibitor and reverse transcriptase inhibitors. Long-term immunoreconstitution, defined as the repopulation of naive CD4+T lymphocytes, will be studied by determining the presence and extent of production of new naive (thymic derived) CD4+T cells and by the ability of patients to mount new helper T cell responses after immunization with influenza and tetanus toxoid. Expansion of T cell receptor will also be explored in subsets of enrolled patients.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA Age greater than 1 year and less than 21 years. Diagnosis of HIV-1 infection as defined by the Centers for Disease Control (CDC). Currently on at least a three drug combination that includes a protease inhibitor (PI) and reverse transcriptase inhibitor (RTI) therapy for at least 6 months. Patient must have received initial protease inhibitor treatment in studies in the HIV and AIDS Malignancy Branch but need not be enrolled on another NIH study to be eligible for this protocol. Age-adjusted CD4+ T lymphocytes greater than 200 cells/ml. Measurements of CD4+45RA+ and CD4+45RO+ T lymphocytes taken within 9 weeks of the time of initiation of protease-inhibitor therapy. Availability of a parent or guardian to provide informed consent. EXCLUSION CRITERIA Critically ill or clinically unstable child. Patients receiving treatment for an infection that requires prolonged treatment must have been stable on therapy for at least 14 days prior to study entry. Administration of chemotherapeutic agents or use of immunomodulating agents such as high dose corticosteroids, interferons, pentoxifylline, G-CSF/GM-CSF, erythropoietin, growth hormone and other growth factors within one month of enrollment. However, patients on anti-inflammatory drugs or stable doses of immunoglobulins (including hyperimmune immunoglobulin) will be eligible unless the latter are directed at a T-cell specific antigen. Sexually active post-menarchal female unwilling to use a barrier method of contraception or unwilling to remain sexually abstinent. Patients who, in the opinion of the Protocol Chairperson or Principal Investigator: may not be likely to benefit from this study, may be put at undue risk by participation in this study, are unlikely to comply with the study requirements.
Total Enrollment: 50
Location and Contact Information:
National Cancer Institute (NCI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Clinical Support Center/NCI 1-888-624-1937
Additional Information:
Study ID Numbers: 990134; 99-C-0134
Study Start Date: July 7, 1999
Record last reviewed: June 1, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001826
Other Hiv Infection Studies:
1. Intermittent Versus Continuous Medication in the Treatment of HIV
2. Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients
3. Combination Therapy with IL-2 Plus Antiretroviral Drugs to Treat HIV Infection
4. Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant Women
5. Magnetic Resonance Imaging of the Face and Bones
Related Studies:
Other HIV Infection Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor
|
|
|
|
|
|
|
|
